# CART-19 Immunotherapy in Mantle Cell Lymphoma

> **NCT02081937** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 2 (estimated)

## Conditions studied

- Hematopoietic/Lymphoid Cancer
- Non-hodgkin Lymphoma,B Cell
- Mantle Cell Lymphoma

## Interventions

- **BIOLOGICAL:** anti-CD19-CAR vector-transduced T cells

## Key facts

- **NCT ID:** NCT02081937
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-03
- **Primary completion:** 2018-12
- **Final completion:** 2019-12
- **Target enrollment:** 2 (ESTIMATED)
- **Last updated:** 2014-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02081937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02081937, "CART-19 Immunotherapy in Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02081937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*